TW202509036A - 黑皮質素２型受體拮抗物 - Google Patents

黑皮質素２型受體拮抗物 Download PDF

Info

Publication number
TW202509036A
TW202509036A TW113117957A TW113117957A TW202509036A TW 202509036 A TW202509036 A TW 202509036A TW 113117957 A TW113117957 A TW 113117957A TW 113117957 A TW113117957 A TW 113117957A TW 202509036 A TW202509036 A TW 202509036A
Authority
TW
Taiwan
Prior art keywords
substituted
group
pyridine
compound
mmol
Prior art date
Application number
TW113117957A
Other languages
English (en)
Chinese (zh)
Inventor
松本重充
義
佐佐木聡
生駒実
福士英人
原亮磨
麻野耕平
渡部浩史
荻野正樹
河西静夫
前川毅志
廣瀬英喜
Original Assignee
日商思可海雅藥品股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商思可海雅藥品股份有限公司 filed Critical 日商思可海雅藥品股份有限公司
Publication of TW202509036A publication Critical patent/TW202509036A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW113117957A 2023-05-16 2024-05-15 黑皮質素２型受體拮抗物 TW202509036A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023080580 2023-05-16
JP2023-080580 2023-05-16

Publications (1)

Publication Number Publication Date
TW202509036A true TW202509036A (zh) 2025-03-01

Family

ID=93519713

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113117957A TW202509036A (zh) 2023-05-16 2024-05-15 黑皮質素２型受體拮抗物

Country Status (13)

Country Link
EP (1) EP4714953A1 (https=)
JP (1) JPWO2024237266A1 (https=)
KR (1) KR20260009350A (https=)
CN (1) CN120858097A (https=)
AR (1) AR132690A1 (https=)
AU (1) AU2024273541A1 (https=)
CL (1) CL2025003547A1 (https=)
CO (1) CO2025012255A2 (https=)
IL (1) IL324502A (https=)
JO (1) JOP20250278A1 (https=)
MX (1) MX2025013542A (https=)
TW (1) TW202509036A (https=)
WO (1) WO2024237266A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL360855A1 (en) * 2000-06-28 2004-09-20 Pfizer Products Inc. Melanocortin receptor ligands
AU2019280689B2 (en) 2018-06-05 2024-09-05 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US12479825B2 (en) * 2019-11-07 2025-11-25 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
JP7734571B2 (ja) 2021-11-30 2025-09-05 株式会社日立製作所 プロセスモデル構築システム、プロセスモデル構築方法

Also Published As

Publication number Publication date
JPWO2024237266A1 (https=) 2024-11-21
EP4714953A1 (en) 2026-03-25
CO2025012255A2 (es) 2025-09-18
CL2025003547A1 (es) 2026-02-20
AR132690A1 (es) 2025-07-23
IL324502A (en) 2026-01-01
KR20260009350A (ko) 2026-01-19
CN120858097A (zh) 2025-10-28
MX2025013542A (es) 2025-12-01
AU2024273541A1 (en) 2025-11-06
JOP20250278A1 (ar) 2025-11-09
WO2024237266A1 (ja) 2024-11-21

Similar Documents

Publication Publication Date Title
KR102642203B1 (ko) 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법
EP3728238B1 (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
CN111356680B (zh) Nlrp3炎性体的选择性抑制剂
CN110621670B (zh) 作为布鲁顿氏酪氨酸激酶的抑制剂的苯并氮杂卓类似物
CN109069869B (zh) 双环pad4抑制剂
TWI768557B (zh) 作為ｈｄａｃ抑制劑之3-烷基-4-醯胺基-雙環[4,5,0]羥肟酸
CN108697710B (zh) 作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物
JP2021521112A (ja) タンパク質分解の調節因子および関連する使用方法
JP6746613B2 (ja) ウレア誘導体、またはその薬理学的に許容される塩
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
CN103781776A (zh) 用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物
CN120584106A (zh) Nlrp3炎性小体抑制剂
CN114641466A (zh) 磺酰脲衍生物及其用途
CN107207512B (zh) 对呼吸道合胞病毒(rsv)的复制具有抑制活性的哌啶取代的三环吡唑并[1，5-a]嘧啶衍生物
WO2021020585A1 (ja) 複素環化合物
TW202509036A (zh) 黑皮質素２型受體拮抗物
CN119654317A (zh) 用于治疗癌症的取代双环杂芳基磺酰胺衍生物
CN110272416A (zh) 吡唑并[3,4-c]吡啶-7-胺衍生物及其制备方法和应用
EP4531849A1 (en) Heterocyclic pad4 inhibitors
WO2026055780A1 (en) Compounds and compositions for treating mc4r related conditions
WO2026055782A1 (en) Compounds and compositions for treating mc4r related conditions
CN119855589A (zh) 杂环pad4抑制剂
EA047011B1 (ru) Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы
HK40041233A (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
HK40025170A (en) Chemical compounds